neurology

Health Lauren Gravitz

Scientists are finding increasing evidence for a link between air pollution and neurodegenerative diseases like Alzheimer’s

The Pharmalot View Ed Silverman

STAT Plus: Why a tone-deaf Regeneron executive deserved to be booed over Alzheimer’s drug remarks

Biotech Matthew Herper and Allison DeAngelis

STAT Plus: ‘This is not a cure’: Consensus begins to emerge on new Alzheimer’s drug

First Opinion Earl Smith

Victims of domestic abuse should get the same top-notch concussion care as athletes

Living With Isabella Cueto

Lessons from a thriving physical therapist to a younger self just learning about multiple sclerosis

Biotech Allison DeAngelis

STAT Plus: Triplet Therapeutics, biotech company focused on Huntington’s, quietly shuts down

Exclusive Mario Aguilar

STAT Plus: Alzheimer’s clinical trials have a recruitment problem. Telehealth platform Ro thinks it can help 

Health Andrew Joseph

STAT Plus: An Alzheimer’s therapy scores winning results, but what could it mean for patients?

Health Jonathan Wosen

Daily multivitamins improved the brain function of seniors in a trial — but plenty of questions remain

First Opinion Podcast Patrick Skerrett

Listen: A doctor with ALS laments the slow pace for drug approval

Biotech Jason Mast

STAT Plus: How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy

Health Tech Casey Ross

STAT Plus: In early research, an AI model detects signs of Parkinson’s using breathing patterns

Health Akila Muthukumar

New research finds blood tests can predict severe outcomes of brain injury

Biotech Adam Feuerstein

STAT Plus: FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results

Biotech Adam Feuerstein

STAT Plus: FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment

Biotech Ryan Cross — The Boston Globe

STAT Plus: Can Biogen’s backup plan for Alzheimer’s succeed?

Health Tech Mario Aguilar

STAT Plus: Startup gets green light to use Apple Watch to track Parkinson’s symptoms

First Opinion Cecille Joan Avila

The often-overlooked connection between traumatic brain injury and domestic violence

In the Lab Jonathan Wosen

The brain ‘learns’ to have seizures more efficiently and frequently over time, mouse study shows

First Opinion Bernard Zipprich

Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?

The Pharmalot View Ed Silverman

STAT Plus: ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval

Health Tech Katie Palmer

STAT Plus: With pharma still struggling in Alzheimer’s, health tech companies want a swing

In the Lab Meghana Keshavan

With new ‘brain-reading’ research, a once-tarnished scientist seeks redemption

D.C. Diagnosis Nicholas Florko

Before Aduhelm, Billy Dunn was a superstar at the FDA

Politics Nicholas Florko

STAT Plus: An ALS therapy sets up a crucial test of the FDA’s independence